20210804_erenumab_Headache_SB_01

Dataset refers to the evaluation of psychological predictors of the outcome of 12-month of treatment with Erenumab in Chronic Migraine patients: Responders (reduction ≥ 50% in migraine days) vs Non Responders (reduction < 50% in migraine days). To this end, patients at baseline received a full psychological evaluation using The Structured Clinical Interview for DSM-5 Clinician Version (SCID-5-CV) to assess mood, anxiety, and personality disorders as well specific questionnaires to evaluate alexithymia traits, childhood traumas, and current life-event stressors. Results highlighted that the presence of current stressors, anxiety and Cluster C personality disorders represent negative predictors of treatment outcome.